Efficacy of Erenumab in Chronic Migraine (CM) Patients with Acute Headache Medication Overuse (MO): A Post Hoc Analysis Assessing Outcomes Using Different Definitions of Remission

Stewart J. Tepper, MD

AHSAM 2020 - Poster session
Published on September 3, 2020

3 minute listen

1 minute read

Key messages

  • This post hoc analysis of a double-blind, placebo-controlled, 12-week study in chronic migraine (CM) evaluated the effect of erenumab on remission from medication overuse (MO) in patients with CM who lacked success with ≥ 1 prior preventive therapy.
  • Erenumab significantly reduced monthly acute headache medication days compared with placebo in CM patients with MO who had lack of success with prior preventive treatment.
  • Across all definitions of remission from medication overuse, erenumab 140 mg consistently demonstrated numerically better outcomes than erenumab 70 mg.
  • Podcast by Stewart J. Tepper, MD

Key messages

  • This post hoc analysis of a double-blind, placebo-controlled, 12-week study in chronic migraine (CM) evaluated the effect of erenumab on remission from medication overuse (MO) in patients with CM who lacked success with ≥ 1 prior preventive therapy.
  • Erenumab significantly reduced monthly acute headache medication days compared with placebo in CM patients with MO who had lack of success with prior preventive treatment.
  • Across all definitions of remission from medication overuse, erenumab 140 mg consistently demonstrated numerically better outcomes than erenumab 70 mg.

Podcast by Stewart J. Tepper, MD

Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Lebanon, NH, New Hampshire

Stewart J. Tepper, MD, FAHS, Professor of Neurology at the Geisel School of Medicine at Dartmouth, is Director of the Dartmouth Headache Center at Dartmouth-Hitchcock Medical Center. Dr Tepper received his BA from Yale and MD from Cornell, completing Neurology residency at Harvard, and is board certified in Headache Medicine (2006-present).
Dr Tepper is Co-director of the Scottsdale Headache Symposium course (2008-present). He is Editor-in-Chief of Headache Currents and an Associate Editor of Headache. He has published more than 430 peer-reviewed manuscripts, editorials, and books on Headache Medicine. Dr Tepper serves on the AHS and AMF Board of Directors and as the Corporate Liaison for AHS.

Stewart J. Tepper, MD: Acorda (Consulting) (Consulting Fees (e.g., advisory boards))



Headache
Clinical Trials


Scan to open on your mobile device